Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
about
Hypertriglyceridemia and Cardiovascular Diseases: RevisitedLipids, blood pressure and kidney update 2015Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitmThe Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisTreatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State.Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.Translational and Therapeutic Approaches to the Understanding and Treatment of DyslipidemiaProgress and future opportunities in the development of vaccines against atherosclerosis.Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatmentCETP Inhibition in CVD Prevention: an Actual Appraisal.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- Mice.Design, Synthesis and Biological Evaluation of N,N-Substituted Amine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors.Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice.ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.[Dyslipidemias : Diagnostics and management].Research update for articles published in EJCI in 2014
P2860
Q26750954-B4157A86-F564-465B-A6AF-A69EB3B48492Q26771550-BA05155E-F61F-459C-AB21-634E48D45C34Q33643426-B51E9283-6424-4282-BA82-88C91115DC87Q33838927-C7CCB96E-65BB-4A6A-8842-9CACA0E7E142Q33887783-1EE19F99-257E-4910-A3ED-40936A12B072Q35953512-238DEE4B-88EF-4599-B6E6-DC46E1723B83Q37013499-FD9AFA9C-75C1-4887-A5C8-5AE3F9B73171Q37036108-AC5CEA15-E882-49A9-890C-49A9E18B0215Q37835406-DB089D52-5C35-4229-B55C-CF657285CE9FQ38631018-ED0ABB0C-7E51-4470-9847-AA31B353B8E7Q38653210-3409B745-A4B0-4655-BFC4-205652BE952BQ38757894-A31C0AB0-62D3-4755-B497-4B73E9439010Q38784639-3FCA5D45-A9BA-460A-8C45-89E4546A9DF4Q38786058-A27B11DC-2329-4803-8016-DCB36873772FQ38832774-0B7D1235-48AC-45DE-ACBD-C4FFF777BE9CQ39320394-779B5732-EAB5-4EB6-9D58-608CF5A862FFQ41705191-2D16B3E3-7BCE-47B4-9E9B-7214BD1B7C3AQ47708252-A9967DEF-2D7E-44A8-82D3-62A2657C641EQ47990605-E18A4937-9CB7-4211-92BA-02AE189971C0Q49087277-DCC5879A-25FB-4561-8E9A-C8A74E84472AQ51741683-462E1678-C3BC-45E2-8E34-655B388C16F6Q51829541-5BB47825-A226-4471-8215-AC136D772BD0Q58197547-A8FF5E55-0C7E-48AD-B83C-FD45A7DA6EF0
P2860
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Assessment of the clinical eff ...... esign of the ACCELERATE trial.
@en
Assessment of the clinical eff ...... esign of the ACCELERATE trial.
@nl
type
label
Assessment of the clinical eff ...... esign of the ACCELERATE trial.
@en
Assessment of the clinical eff ...... esign of the ACCELERATE trial.
@nl
prefLabel
Assessment of the clinical eff ...... esign of the ACCELERATE trial.
@en
Assessment of the clinical eff ...... esign of the ACCELERATE trial.
@nl
P2093
P1476
Assessment of the clinical eff ...... esign of the ACCELERATE trial.
@en
P2093
Alan R Tall
Burkhard Vangerow
C Michael Gibson
Christopher Grainger
Daniel Rader
Ellen McErlean
Giacomo Ruotolo
Govinda J Weerakkody
H Bryan Brewer
Jeffrey Riesmeyer
P304
P356
10.1016/J.AHJ.2015.09.007
P407
P577
2015-09-16T00:00:00Z